326 related articles for article (PubMed ID: 20206456)
21. Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin).
Khera AV; Demler OV; Adelman SJ; Collins HL; Glynn RJ; Ridker PM; Rader DJ; Mora S
Circulation; 2017 Jun; 135(25):2494-2504. PubMed ID: 28450350
[TBL] [Abstract][Full Text] [Related]
22. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.
Ridker PM; Pradhan A; MacFadyen JG; Libby P; Glynn RJ
Lancet; 2012 Aug; 380(9841):565-71. PubMed ID: 22883507
[TBL] [Abstract][Full Text] [Related]
23. The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial.
Novack V; MacFadyen J; Malhotra A; Almog Y; Glynn RJ; Ridker PM
CMAJ; 2012 Apr; 184(7):E367-72. PubMed ID: 22431901
[TBL] [Abstract][Full Text] [Related]
24. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).
Khera AV; Everett BM; Caulfield MP; Hantash FM; Wohlgemuth J; Ridker PM; Mora S
Circulation; 2014 Feb; 129(6):635-42. PubMed ID: 24243886
[TBL] [Abstract][Full Text] [Related]
25. Jupiter to earth: a statin helps people with normal LDL-C and high hs-CRP, but what does it mean?
Shishehbor MH; Hazen SL
Cleve Clin J Med; 2009 Jan; 76(1):37-44. PubMed ID: 19122109
[TBL] [Abstract][Full Text] [Related]
26. Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER).
Ridker PM; MacFadyen J; Libby P; Glynn RJ
Am J Cardiol; 2010 Jul; 106(2):204-9. PubMed ID: 20599004
[TBL] [Abstract][Full Text] [Related]
27. Statin therapy and risk of fracture: results from the JUPITER randomized clinical trial.
Peña JM; Aspberg S; MacFadyen J; Glynn RJ; Solomon DH; Ridker PM
JAMA Intern Med; 2015 Feb; 175(2):171-7. PubMed ID: 25437881
[TBL] [Abstract][Full Text] [Related]
28. Rosuvastatin and the JUPITER trial: critical appraisal of a lifeless planet in the galaxy of primary prevention.
López A; Wright JM
Int J Occup Environ Health; 2012; 18(1):70-8. PubMed ID: 22550699
[TBL] [Abstract][Full Text] [Related]
29. Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study.
Fonseca FA; Izar MC
Expert Rev Cardiovasc Ther; 2009 Sep; 7(9):1041-56. PubMed ID: 19764857
[TBL] [Abstract][Full Text] [Related]
30. Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study.
Glynn RJ; MacFadyen JG; Ridker PM
Clin Chem; 2009 Feb; 55(2):305-12. PubMed ID: 19095726
[TBL] [Abstract][Full Text] [Related]
31. Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ≥ 5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities.
Koenig W; Ridker PM
Eur Heart J; 2011 Jan; 32(1):75-83. PubMed ID: 20971747
[TBL] [Abstract][Full Text] [Related]
32. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease.
Han Y; Zhu G; Han L; Hou F; Huang W; Liu H; Gan J; Jiang T; Li X; Wang W; Ding S; Jia S; Shen W; Wang D; Sun L; Qiu J; Wang X; Li Y; Deng J; Li J; Xu K; Xu B; Mehran R; Huo Y
J Am Coll Cardiol; 2014 Jan 7-14; 63(1):62-70. PubMed ID: 24076297
[TBL] [Abstract][Full Text] [Related]
33. [JUPITER: reduction by rosuvastatin of cardiovascular events and mortality in healthy subjects without hyperlipidaemia but with elevated C-reactive protein].
Scheen AJ
Rev Med Liege; 2008 Dec; 63(12):749-53. PubMed ID: 19180837
[TBL] [Abstract][Full Text] [Related]
34. Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease.
Sawara Y; Takei T; Uchida K; Ogawa T; Yoshida T; Tsuchiya K; Nitta K
Intern Med; 2008; 47(17):1505-10. PubMed ID: 18758125
[TBL] [Abstract][Full Text] [Related]
35. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy.
Mora S; Glynn RJ; Ridker PM
Circulation; 2013 Sep; 128(11):1189-97. PubMed ID: 24002795
[TBL] [Abstract][Full Text] [Related]
36. Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial.
Dugani SB; Akinkuolie AO; Paynter N; Glynn RJ; Ridker PM; Mora S
JAMA Cardiol; 2016 May; 1(2):136-45. PubMed ID: 27347563
[TBL] [Abstract][Full Text] [Related]
37. Estimating treatment effects for individual patients based on the results of randomised clinical trials.
Dorresteijn JA; Visseren FL; Ridker PM; Wassink AM; Paynter NP; Steyerberg EW; van der Graaf Y; Cook NR
BMJ; 2011 Oct; 343():d5888. PubMed ID: 21968126
[TBL] [Abstract][Full Text] [Related]
38. Moving toward new statin guidelines in a post-JUPITER world: principles to consider.
Ridker PM
Curr Atheroscler Rep; 2009 Jul; 11(4):249-56. PubMed ID: 19500487
[TBL] [Abstract][Full Text] [Related]
39. The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin).
O'Keefe JH; Carter MD; Lavie CJ; Bell DS
Postgrad Med; 2009 May; 121(3):113-8. PubMed ID: 19491548
[TBL] [Abstract][Full Text] [Related]
40. Safety profile of subjects treated to very low low-density lipoprotein cholesterol levels (<30 mg/dl) with rosuvastatin 20 mg daily (from JUPITER).
Everett BM; Mora S; Glynn RJ; MacFadyen J; Ridker PM
Am J Cardiol; 2014 Dec; 114(11):1682-9. PubMed ID: 25439449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
